NRIX
Fiscal year ends November Quarters are offset from the calendar — Q1 is Dec–Feb

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and inflammatory diseases. The company utilizes a proprietary DEL-AI discovery engine that integrates DNA encoded libraries, automated chemistry, and machine learning to identify degraders and degrader antibody conjugates (DACs). Its wholly owned pipeline includes bexobrutideg (NX-5948), a selective Bruton’s tyrosine kinase (BTK) degrader; zelebrudomide (NX-2127), a dual degrader of BTK and transcription factors IKZF1 and IKZF3; and NX-1607, an inhibitor of the E3 ligase CBL-B. Nurix also maintains a partnered pipeline with Gilead Sciences, Sanofi, and Pfizer, which includes a clinical stage degrader of IRAK4 (NX-0479/GS-6791) and a preclinical degrader of STAT6. The company targets patients with relapsed or refractory B-cell malignancies, solid tumors, and autoimmune conditions, with regulatory designations from the FDA and EMA for its lead programs.

Summarised from the company's own disclosures, fiscal year ended Jan 2026

Industry Biotechnology Homepage nurixtx.com
Sector Healthcare IR page ir.nurixtx.com
Tags
targeted protein degradation, degrader antibody conjugates, dna encoded libraries, machine learning, oncology, immunology, btk inhibitors, e3 ligase, autoimmune diseases, b-cell malignancies, bexobrutideg, NX-5948, zelebrudomide, NX-2127, NX-1607, NX-0479, GS-6791, DEL-AI, Gilead Sciences, Sanofi, Pfizer
Press page —

Metrics

Valuation  
Market cap $ 1.725B
Market cap (USD) $ 1.725B
P/E 6.87
PEG —
P/BV 1.78
P/S 2.46
P/OCF 4.55
P/FCF 4.66
Dividend yield —
Turnover / mcap —
Returns  
ROE -49.6%
ROI -76.7%
ROIC -62.2%
Profit margin -314.9%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 68
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 83.98M 54.549M 76.987M 38.627M 29.75M 17.82M 31.115M
Net profit -264.457M -193.569M -143.948M -180.36M -117.194M -43.242M -21.699M
Free cash flow -263.467M -181.857M -89.766M -172.051M -90.026M -4.633M -1.05M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 17.07 21.73 5.2 12.88 29.13 34.91 —
Price performance 12m -0.21 3.18 -0.6 -0.56 -0.17 — —

Filed figures

Figure Nov 2018 Nov 2019 Nov 2020 Nov 2021 Nov 2022 Nov 2023 Nov 2024 Nov 2025
Balance sheet detail
Trade receivables (USD) — — — 6M 0.00 — 0.00 0.00
↳ YoY growth -100.0%
Lease liabilities (USD) — — 14.2M 13M 12M 30.6M 28.3M 55.7M
Cash and deposits (USD) 25.6M 34.8M 119M 80.5M 64.5M 54.6M 110M 247M
Right-of-use assets (USD) — — 13.3M 14M 12.3M 31.1M 28.1M 50.5M
Cash flow detail
Operating cash flow (USD) — 601,000 -80,000 -84.4M -160M -81.4M -173M -249M
Purchases of property, plant and equipment (USD) — -1.65M -4.55M -5.66M -12.2M -8.4M -9.27M -14M
Change in receivables (cash effect) (USD) — — — -6M 6M 0.00 0.00 —
Change in payables (cash effect) (USD) — 302,000 1.23M 1.59M 85,000 1.61M 5.21M -630,000
Income taxes paid (cash effect) (USD) — -1,000 -1,000 -481,000 0.00 — — —
Share-based compensation (USD) — 510,000 4.3M 15.8M 28.1M 33.7M 33.9M 38M
Operating cash flow before change in receivables (USD) — — — -78.4M -166M -81.4M -173M —
Free cash flow (OCF - PPE - intangibles) (USD) — -1.05M -4.63M -90M -172M -89.8M -182M -263M
Income detail
Research and development expense (USD) — 45M 66.5M 116M 184M 189M 222M 317M
↳ 5y CAGR +37.5% +36.7%
Total comprehensive income (USD) — -21.7M -43.2M -118M -184M -140M -193M -265M
Comprehensive income to owners (USD) — -21.7M -43.2M -118M -184M -140M -193M -265M
Reported Oct 14, 2020 Feb 16, 2021 Apr 8, 2022 Jan 28, 2022 Feb 9, 2023 Feb 15, 2024 Jul 9, 2025 Oct 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

Updated results show high response rates in patients with prior covalent BTK inhibitor exposure and continued favorable tolerability in relapsed/refractory CLL

BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that new and updated clinical data from its ongoing Phase 1a/1b study evaluating bexobrutideg (NX-5948), the Company’s investigational oral Bruton’s tyrosine kinase (BTK) degrader, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15, 2026 in New Orleans, Louisiana.

The presentation abstract was released today by ASH and highlights new and updated data in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with efficacy data reported for those previously treated with covalent BTK inhibitors (cBTKi). Results demonstrate continued evidence of durable clinical activity and favorable tolerability with bexobrutideg administered at the recommended Phase 2 dose of 600 mg once daily. Additional analyses, including data from BTK inhibitor-naïve and treatment naïve patients and efficacy in patients with high-risk molecular features, will be presented at the meeting.

“Patients with relapsed or refractory CLL/SLL continue to face significant challenges as resistance and intolerance emerge with currently available therapies,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix Therapeutics. “We are encouraged by the growing body of clinical evidence supporting bexobrutideg’s potential to address important unmet needs in patients at early as well as late stages of their therapeutic journeys. The updated data being presented at ASH further underscore the differentiated mechanism of our BTK degrader, including its ability to target both wild-type and mutant forms of BTK, and reinforce our confidence in the ongoing development of bexobrutideg as a potential best-in-class therapy for patients with B-cell malignancies.”

| Poster Presentation Details | |

| Title: | New and updated efficacy and safety data on bexobrutideg (NX-5948), a novel BTK degrader, in patients with relapsed/refractory CLL/SLL and prior cBTKi exposure from an ongoing Phase 1a/b trial |

| Session Name: | 642**.**Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II |

| Presenter: | Nirav Shah, M.D., Medical College of Wisconsin |

| Session Date: | December 13, 2026 |

| Presentation Time: | 12/13/2026 6:00:00 PM - 12/13/2026 8:00:00 PM |

| Room: | Hall F |

About Bexobrutideg (NX-5948)

Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.

​​​Bexobrutideg is currently being evaluated in a broad clinical development program in patients with CLL, including the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed/refractory CLL previously treated with covalent and noncovalent BTKi and a BCL2i; the DAYBreak CLL-306 clinical trial (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg to pirtobrutinib in patients with relapsed/refractory CLL previously treated with a covalent BTKi; the NX-5948-203 Phase 1b/2 clinical trial (NCT07520006), assessing the combination of bexobrutideg with venetoclax in patients with relapsed/refractory CLL and potentially treatment-naïve CLL; and the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and a clinical-stage degrader of IRAK4 in collaboration with Gilead. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Nurix aims to establish degrader-based treatments at the forefront of patient care. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the Nurix’s intention to present updated data from the Phase 1a/1b study evaluating bexobrutideg at the 68th American Society of Hematology Annual Meeting, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended August 31, 2026, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Nurix Therapeutics, Inc. — Other Events Bull 0 Bear 5 Clinical/regulatory

On November 3, 2026, Nurix Therapeutics, Inc. (the “Company”) announced that collaboration partner Sanofi S.A. (“Sanofi”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. As a result of Sanofi’s decision, the Company does not expect to receive any of the future development, regulatory and commercial milestone payments or royalties for which it was eligible under the Company’s collaboration with Sanofi (the “Sanofi Collaboration”) with respect to the SAR448272 program. The Company remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the Sanofi Collaboration that Sanofi may at its discretion develop further into clinical candidates. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

November 3, 2026

PDF Version

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.

As a result of Sanofi’s decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the collaboration agreement that Sanofi may at its discretion develop further into clinical candidates. Today’s announcement does not change Nurix’s recently issued cash runway guidance, with cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, sufficient to fund operations into the second half of 2029.

“While today’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “Bexobrutideg, our lead BTK degrader program partnered with Roche, is advancing in a Phase 3 trial in patients with chronic lymphocytic leukemia; our wholly owned CBL-B inhibitor NX-1607 is advancing in multiple Phase 1b cohorts for patients with lung cancer, colon cancer, prostate cancer, and melanoma; and our IRAK4 degrader for rheumatoid arthritis, GS-6791/NX-0479 is advancing through Phase 1 trials with our partner Gilead.”

About the Nurix/Sanofi Collaboration Under the 2019 collaboration agreement, Nurix deployed its proprietary DEL-AI drug discovery platform to identify novel agents that utilize E3 ligases to induce the degradation of specified proteins. In 2025, Sanofi exercised its license extension option for two programs targeting transcription factors for the treatment of autoimmune/inflammatory diseases including an undisclosed target and STAT6. For both programs, Nurix retains the option to co-develop and co-promote in the United States following demonstration of clinical proof of concept.

About Nurix Therapeutics Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical stage oncology pipeline includes bexobrutideg, a degrader of Bruton’s tyrosine kinase (BTK), being co-developed in collaboration with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix's autoimmune disease pipeline includes bexobrutideg, being developed in collaboration with Roche and a clinical-stage IRAK4 degrader, being developed in collaboration with Gilead. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its wholly owned preclinical pipeline as well as those under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential receipt of future payments under the Company’s collaborations and statements regarding the Company’s projected ability to fund operations into the second half of 2029. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Those risks include the risk that Sanofi may choose not to advance other licensed programs, the risk that collaborators may discontinue or delay the development of partnered programs, and the other risks described under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2026, and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this report, and the Company undertakes no obligation to update them, except as required by law.

Investors and Media

Kris Fortner Nurix Therapeutics, Inc. [email protected]

Prompts

Nurix Therapeutics, Inc. (ticker NRIX), listed in United States.

Company History

Date Change Detail
Mar 26, 2020 Renamed Nurix, Inc. → NURIX THERAPEUTICS, INC.

ETFs Holding Nurix Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 2.18% 2,790,715 $ 39.74M Nov 18, 2026
ILDR 0.32% 69,328 $ 1.021M Nov 16, 2026
FSEG 0.16% 374 $ 9,073.24 Jun 30, 2026
FSEV 0.14% 386 $ 9,364.36 Jun 30, 2026
FFSM 0.11% 71,221 $ 1.653M Jul 31, 2026
RESM 0.08% 114 $ 2,765.64 Jun 30, 2026
FESM 0.06% 145,491 $ 3.53M Jun 30, 2026
DFAS 0.02% 525,138 $ 8.192M Nov 12, 2026
VFMO 0.02% 17,600 $ 453.728K Aug 31, 2026
MSSM 0.01% 3,984 $ 102.708K Aug 31, 2026
DFAC 0.00% 131,270 $ 2.048M Nov 12, 2026
DFAU 0.00% 17,593 $ 274.451K Nov 12, 2026
DFUS 0.00% 12,499 $ 194.984K Nov 12, 2026
DCOR 0.00% 22,037 $ 343.777K Nov 12, 2026